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Research
The classic description of lead neuropathy is
that of a motor neuropathy that typically pre-
sents as wrist drop. More recently, investigators
demonstrated that, in the development of lead
neuropathy, sensory nerve ﬁbers are affected ear-
lier than motor nerve fibers (Chuang et al.
2000; Kovala et al. 1997; Rubens et al. 2001;
Schwartz et al. 2001; Singer et al. 1983), and
nerve conduction studies showed mild slowing
of both sensory and motor conduction velocities
as well as diminished amplitude of the sensory
potential (Araki et al. 1986; Ashby 1980; Baker
et al. 1984; Bordo et al. 1982; Buchthal and
Behse 1979; Catton et al. 1970; Chen et al.
1985; Chia et al. 1996a, 1996b; Jeyaratnam
et al. 1985; Kovala et al. 1997; Pasternak et al.
1989; Rubens et al. 2001; Seppäläinen and
Hernberg 1980; Seppäläinen et al. 1979; Singer
et al. 1983; Yeh et al. 1995). After reviewing the
lead neuropathy literature from 1974 to 1984,
Ehle (1986) concluded that sensory nerve con-
duction is more likely to be affected than is
motor nerve conduction, that the upper
extremities are more likely to be involved than
the lower extremities, and that these effects usu-
ally occur after a year of lead exposure, with a
continuous linear relationship between blood
lead and nerve conduction velocity only when
blood lead exceeded 70 µg/dL.
In evaluating peripheral nerve function,
electrodiagnostic testing examines the integrity
of only large myelinated nerve ﬁbers with the
fastest conduction velocities. Current percep-
tion threshold (CPT), a neuroselective test,
measures sensory nerve conduction threshold
in three nerve ﬁber populations—large myeli-
nated (Aβ), small myelinated (Aδ), and
unmyelinated (C) nerve ﬁbers. In peripheral
neuropathies associated with a variety of med-
ical conditions, CPT abnormalities have
demonstrated good agreement with nerve con-
duction studies (Katims et al. 1989; Rendell
et al. 1989; Weseley et al. 1989). Additionally,
pathology in the small myelinated and
unmyelinated nerve fibers shown with CPT
but not detected by routine nerve conduction
studies occur in Fabry’s disease (Ro et al.
1999), diabetic and alcoholic C-fiber neu-
ropathies (Oishi et al. 2002), arsenic exposure
(Tseng 2003), and leprosy (Katims J, person-
nel communication). Capsaicin, a topical drug
for pain relief that affects small nerve fibers,
was found to elevate CPT thresholds for small
myelinated and unmyelinated nerve ﬁbers but
not for large myelinated nerve fibers (Kiso
et al. 2001).
In the past, the usual biomarker used to
study lead neuropathy was PbB, a blood lead
measure of recent exposure (Bordo et al.
1982; Davis and Svendsgaard 1990, Pasternak
et al. 1989; Rubens et al. 2001). More recently,
studies have shown an association between
several biomarkers of chronic lead exposure—
working lifetime-weighted average blood lead
(TWA), working lifetime-integrated blood
lead (IBL), and bone lead (PbBn)—and
impairment of peripheral nerve function at a
time when concurrent PbB was not elevated
(Chia et al. 1996a; Chuang et al. 2000;
Kovala et al. 1997; Schwartz et al. 2001;
Triebig et al. 1984; Yeh et al. 1995). Which
of these is the best metric for modeling
chronic lead effects on the peripheral nerve
remains to be demonstrated.
In the older literature, lead poisoning pre-
sented as muscle paralysis, typically occurring
in the muscles most used (Aub et al. 1925).
In fact, patterns of weakness differed by occu-
pation but did not necessarily follow the dis-
tribution of a specific nerve (Cantarow and
Trumper 1944). Although it is established
that lead impairs peripheral nerve function,
not studied to date is the effect of the interac-
tion between lead exposure and chronic
repetitive muscle use on that function.
We report here on the use of CPT to
examine different nerve fiber populations in
the upper extremities of a group of current
lead workers with substantial chronic lead
exposure and a broad range of ergonomic
stressors (ESs).
Materials and Methods
Subjects. A screening neuropsychological bat-
tery had been administered to 468 current and
retired smelter workers by testers blinded to the
degree of lead exposure of the worker. If perfor-
mance on two or more tests in any functional
domain was < 1.5 SDs compared with age-
matched norms, the worker was invited for a
complete clinical evaluation. Eighty current
workers were identified by this criterion.
Bleecker et al. (1995, 1997, 2002, 2003) and
Lindgren et al. (1996) have described other
aspects of these samples in previous publica-
tions. All participants volunteered for the study
and signed an informed consent form approved
by a combined provincial management–labor
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Baltimore, approved the PbBn protocol.
Exposure. As employees of a primary
smelter (located in New Brunswick, Canada),
participants were routinely exposed to several
sources of inorganic lead dust and, to a lesser
extent, lead fumes. Since the smelter began
operations in 1966, PbB levels of all employees
have been checked at least quarterly. The fre-
quency of PbB measurements depended on the
relative degree of lead exposure of any given job
and whether the employee had been relocated
because of lead exposure. PbB levels precipitat-
ing relocation dropped from 90 µg/dL in 1966
to 75 µg/dL in 1974, 65 µg/dL in 1987, and 50
µg/dL in 1990. In general, the smelter workers
in this study had chronic inorganic lead expo-
sure that had been high in the distant past but
lower in the more proximate past, with rela-
tively low PbB levels at the time of this study.
Blood samples for lead testing had been
collected preshift by the facility nursing staff
in the inﬁrmary, a building physically distinct
from the smelter, using standard techniques to
minimize the likelihood of lead contamination
of the samples. A local off-site laboratory using
the dithizone method initially performed sam-
ple analysis. By the early 1970s, these analyses
were conducted by a regional contract labora-
tory using graphite-furnace atomic-absorption
spectrophotometry; this laboratory subse-
quently became a participant in the interlabo-
ratory blood lead proﬁciency testing program
of the then–U.S. Centers for Disease Control.
Results of this proficiency testing showed
good agreement. For the purpose of this
study, blood lead results from the two differ-
ent laboratories were considered equivalent.
We calculated the lead levels used to
determine IBL, a measure of cumulative
blood lead, as the sum—over each partici-
pant’s working lifetime—of the products of
each PbB level and one-half the time interval
from the preceding blood lead to the follow-
ing blood lead measure. TWA, the measure of
average intensity of lead exposure over the
period of employment, was created by divid-
ing IBL by total years of employment at the
smelter. To examine the effect of the amount
of time a subject’s blood lead concentration
was above a criterion level, we also created a
series of metrics—IBL20, IBL30, IBL40,
IBL50, IBL60—calculated in the same man-
ner as IBL but including only areas under the
time–blood lead curve that were above
increasingly higher criterion blood lead levels;
for example, IBL20 µg/dL was calculated by
cumulating only that part of the area under
the curve > 20 µg/dL (Figure 1). PbB was
obtained on the day of testing. PbBn analysis,
previously described (Bleecker et al. 1995),
used the methods of Chettle et al. (1991).
Measurements made at the mid-tibia with
K-shell X-ray fluorescence were performed
at the University of Maryland Toxicology
Program laboratories.
Working-lifetime weighted-average ES. An
ES rating was created with the assistance of the
smelter safety committee, who reviewed all
jobs ever worked by the participants and strat-
ified them on a three-tiered ordinal scale.
Using the method of Moore and Garg (1995),
we converted the ordinal scale to interval with
the following weights: 1, light; 6, medium;
and 18, heavy. We then cumulated over each
participant’s employment history the products
of duration of time worked in a given job and
the job’s assigned ES weight. From this, we
calculated a time-weighted average ES.
Current perception threshold. CPT meas-
ures the minimum transcutaneous current
intensity needed to produce a sensation
(Neurometer, Neurotron Inc., Baltimore,
MD). Because it uses a constant alternating
current, there is no change in current intensity
with variations in skin impedance. The sinu-
soidal waveform of the alternating current
excites different subpopulations of nerve ﬁbers
as a function of frequency: 2,000 Hz, large
myelinated fibers; 250 Hz, small myelinated
ﬁbers; and 5 Hz, small unmyelinated ﬁbers.
Electrodes were attached to the dorsolateral
aspect of the fourth digit of the nondominant
hand. CPT was initially approximated by the
“method of limits,” where the current was
increased until the worker reported a sensation
(i.e., buzzing). To more precisely ascertain
threshold, the current was decremented and
reincremented until a range was reached where
a stimulus was correctly identiﬁed at one inten-
sity and not at a slightly lower one for three
consecutive trials. During this part of the test-
ing, the stimulus presentation used a “forced
choice method” paradigm with the presenta-
tion of a real and placebo stimuli. The proce-
dure was repeated for all three frequencies at
each site and are referred to in this article as
CPT2000, CPT250, and CPT5.
Data analyses. Before the analyses, we
examined age, current alcohol use, current
smoking, ES, and the lead exposure metrics
using univariate descriptive statistics to check
for accuracy of data entry, missing values, and
assumptions underlying multivariate analysis.
Four individuals had values > 2.5 SDs above
the mean of the CPT score and considered
univariate outliers; one individual was identi-
ﬁed through Mahalanobis distance as a multi-
variable outlier with p < 0.001. One individual
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Figure 1. IBL above increasing criterion PbB levels, as shown by the shaded area under the curve. (A) IBL;
(B) IBL20; (C) IBL30; (D) IBL40; (E) IBL50; (F) IBL60.
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viduals for analysis. Those removed were not
significantly different from the remaining
sample on the independent variables or the
covariates.
SPSS-PC (version 12.0.1; SPSS Inc.,
Chicago, IL) was used for data analyses. The
determination of covariates was based on risk
factors associated with the development of a
peripheral neuropathy. These included age,
dichotomous current smoking, dichotomous
current alcohol use, and working-lifetime
weighted-average ES. Other medical condi-
tions commonly associated with peripheral
neuropathy were not present. The three CPT
measures were modeled using multiple linear
regression with the measures of lead dose, PbB,
TWA, IBL, IBL20, IBL30, IBL40, IBL50,
IBL60, and PbBn after adjusting for the
covariates. Additionally, on the basis of a priori
considerations (Hopkins and Morgan-Hughes
1969; Jacobs and Le Quesne 1984), we mod-
eled the interaction between ES and each of
the exposure variables in these regressions.
Results
Demographic data for the 74 workers included
in the analyses are presented in Table 1, along
with mean values for the four measures of lead
exposure and the outcome measures of CPT by
frequency. As expected, thresholds by ﬁber pop-
ulation decreased from large myelinated nerve
ﬁbers to small myelinated nerve ﬁbers and more
so for small unmyelinated nerve ﬁbers.
Table 2 presents the results of the unique
variance contributed to CPT by the measure of
lead dose after adjustment for the covariates.
Of the simple exposure variables, IBL, TWA,
PbB, and PbBn, only the two based on cumu-
lative blood lead levels—IBL and TWA—were
signiﬁcantly related to CPT, and in both cases
only to CPT2000, after adjusting for the covari-
ates. IBL explained 3.9% of the variation in
CPT2000 (p < 0.08). Regression diagnostics
revealed nonlinearity in the relationship
between TWA and CPT2000, which was
addressed by including a quadratic term in the
model. Combined, the TWA and TWA2
terms accounted for 8.7% of the variation in
CPT2000 (p < 0.03). The calculated minimum
for the quadratic relationship for TWA and
CPT2000 was 28 µg/dL (Figure 2).
To examine the contribution to CPT by
exposure above different blood lead levels,
we stratified IBL by the cumulative time a
subject’s PbB was above different criterion
levels—IBL above a PbB level of 20 µg/dL
(n = 74), 30 µg/dL (n = 73), 40 µg/dL (n =
70), 50 µg/dL (n = 68), and 60 µg/dL (n =
61). The different sample sizes at each level
reflect workers who did not have PbB that
reached the required level. In Table 3, separate
linear regressions revealed the unique variance
that IBL20, IBL30, IBL40, IBL50, and IBL60
each contributed to the three frequencies of
CPT, after adjusting for age, smoking, alcohol
use, and ES. As the criterion PbB level
increased from IBL20 through IBL60, so did
the percentage of CPT2000 variance explained,
with ∆R2 ranging from 5.8% (p < 0.03) for
IBL20 to 23.3% (p < 0.00) for IBL60. Only
IBL60 accounted for a signiﬁcant amount of
variance of CPT250, reﬂecting increased nerve
damage with time spent at PbB > 60 µg/dL.
Despite diminished power with IBL60 due to
a smaller sample size, the dose effect remained
signiﬁcant.
To address the interaction of motor activ-
ity and lead toxicity on the peripheral nerves,
we tested interaction terms created by multi-
plying the IBL variables based on the increased
criterion blood lead levels × ES with multiple
linear regression, controlling for the covariates
and base terms. The strength of association of
the interaction term with CPT2000 increased
from IBL20 × ES (R2 = 1.1%, p = not signiﬁ-
cant) to IBL60 × ES (R2 = 6.1%, p < 0.02).
The interaction is shown in Figure 3 as hetero-
geneity of regression slopes in the two groups
stratiﬁed by high and low ES, suggesting that
in the presence of high ES there is an enhanced
lead effect on the peripheral nerve.
Discussion
In this group of lead-exposed workers, IBL and
TWA, two measures of chronic lead exposure,
were significantly related to decrements in
peripheral nerve function as measured by CPT,
whereas PbBn and PbB were not. PbBn, with a
half-life of 17–25 years, is a measure of lead
stored in the bone compartment and is not a
consistent biomarker of lead effect in the ner-
vous system (Bleecker et al. 1997; Hanninen
et al. 1998; Kovala et al. 1997). Also, PbB,
with a half-life of 30 days, is a weak measure of
lead exposure for the peripheral nervous system
as demonstrated in a meta-analysis of 32 elec-
trodiagnostic studies of lead neuropathy (Davis
and Svendsgaard 1990). With ongoing expo-
sure, lead accumulates in the nervous system
and is retained there even as PbB falls. This
accounts for the lack of a consistent relation-
ship between lead content in the nervous sys-
tem and PbB (Cantarow and Trumper 1944;
Feldman et al. 1977; Goldstein et al. 1974).
Because lead neuropathy requires exposure for
months to years, it is not surprising that PbB, a
biomarker reflecting recent exposure, has an
inconsistent association with this outcome.
Other studies have found measures of chronic
lead exposure associated with changes in nerve
conduction velocity at a time when PbB was
not (Chia et al. 1996a, 1996b). However,
measures of chronic lead exposure associated
with vibration thresholds or nerve conduction
studies continue to vary among the published
studies, from PbBn (Schwartz et al. 2001) to
TWA (Chuang et al. 2000; Seppäläinen et al.
1979; Triebig et al. 1984) to IBL (Chia et al.
1996a, 1996b; Kovala et al. 1997; Yeh et al.
1995). A Finnish study (Kovala et al. 1997)
demonstrated that IBL had a stronger relation-
ship than did PbBn with nerve conduction
studies, a ﬁnding similar to that of this study.
The strength of IBL as a measure of
cumulative exposure improved when the
amount of time at lower blood lead levels was
Bleecker et al.
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Table 1. Descriptive statistics on demographics, exposure, and ﬁnger CPT for 74 current smelter workers.
Variable Mean ± SD Minimum–maximum
Age (years) 44 ± 8.4 24 to 64
Education (years) 8 ± 2.8 0 to 13
Years employed 20 ± 5.3 4 to 26
Current alcohol users (%) 60 —
Current smokers (%) 14 —
PbB (µg Pb/dL) 26 ± 7.1 13 to 43
IBL (µg-year/dL) 891 ± 298.8 81 to 1,376
TWA (µg Pb/dL) 42 ± 8.4 17 to 57
PbBn (µg Pb/g bone mineral)  40 ± 23.8 –12 to 90
CPT2000 Hz (mA)  330 ± 72.4 180 to 512
CPT250 Hz (mA)  134 ± 50.5 32 to 278
CPT5 Hz (mA) 83 ± 37.9 16 to 190
Values are mean ± SD except where noted.
Table 2. Unique variance (%) of CPT in the finger
explained by measures of lead dose.
Variable CPT2000 CPT250 CPT5
IBL (µg-year/dL) 3.9* 0.4 0.0
TWA (µg Pb/dL) — 0.8 0.3
TWA + TWA2 (µg Pb/dL) 8.7** — —
PbBn (µg Pb/g bone mineral) 1.8 1.3 0.8
PbB (µg Pb/dL) 0.2 1.8 0.3
∆R2 for exposure only. Analyses controlled for age, alcohol,
smoking, and ESs.
*p < 0.08, **p < 0.03.
Figure 2. Predicted curvilinear relationship
between TWA and CPT2000. CB, conﬁdence bound.
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at 28 µg/dLnot included in the exposure term. This
resulted in an increased strength of the linear
model from ∆R2 for IBL = 3.9% (p < 0.08) to
∆R2 for IBL20 = 5.8% (p < 0.03). One possi-
ble explanation is that blood lead levels less
relevant to the outcome were removed. This
would result in improved precision of meas-
urement due to a decreased nondifferential
exposure misclassiﬁcation.
IBL is a term composed of duration and
intensity of exposure; however, the mean dura-
tion of lead exposure in the literature reporting
significant association between IBL and
peripheral nerve conduction parameters varies
from 2.5 years (Yeh et al. 1995), to 5.3 years
(Chia et al. 1996a, 1996b), to 16 years (Kovala
et al. 1997), to 20 years in the present study
with CPT. Despite decreased duration spent at
the increasing criterion blood lead level, the
variance accounted for by the exposure term
increased, suggesting that average intensity
may be more critical than duration of exposure
for neurotoxicity in the peripheral nerves. In
the present study, the absence of a signiﬁcant
relationship between years employed and
CPT2000 is consistent with this hypothesis.
As reported by Ehle (1986), an association
of nerve conduction studies with lead exposure
occurred when PbB exceeded 70 µg/dL; how-
ever, an increasing number of studies are ﬁnd-
ing this association at much lower PbB levels.
Chuang et al. (2000) found a threshold curve
for vibration perception at a mean PbB level of
31 µg/dL. Chia et al. (1996a, 1996b) and
Chen et al. (1985) suggested that the threshold
effect for changes in nerve conduction studies
occurs at a PbB level of 40 µg/dL, whereas
Seppäläinen et al. (1983) showed that it was
closer to 30 µg/dL. Yeh et al. (1995) found
electromyographic abnormalities beginning at
PbB levels of 17 µg/dL. In this study, there was
no association of CPT and PbB; however, the
curve minimum of TWA was at 28 µg/dL.
This association of low PbB with nerve func-
tion may be caused by the attention given sen-
sory nerve ﬁbers that are affected earlier in the
development of lead neuropathy (Ehle 1986;
Rubens et al. 2001; Singer et al. 1983).
CPT for large myelinated fibers showed
that these were the primary nerve fibers
affected by lead exposure. Vibration percep-
tion thresholds also carried by large myeli-
nated fibers is associated with chronic lead
exposure (Chuang et al. 2000; Kovala et al.
1997; Schwartz et al. 2001). These findings
agree with neuropathology of a biopsy of
human lead neuropathy that found loss of the
large myelinated nerve fibers in a sensory
nerve (Buchthal and Behse 1979). CPT pro-
vided neuroselective stimuli that allowed for
detection of expanded pathology at IBL60
with involvement of large (CPT2000) and
small (CPT250) myelinated nerve ﬁbers, a bio-
logically plausible ﬁnding.
Lead affects the upper extremities more
frequently than the lower extremities (Chuang
et al. 2000; Ehle 1986; Pasternak et al. 1989;
Schwartz et al. 2001; Yeh et al. 1995). Dermal
absorption of inorganic lead is minimal com-
pared with inhalation and oral absorption.
However, direct cutaneous exposure in the
upper extremities may occur through skin
absorption, as reported in humans with lim-
ited exposure in an experimental setting
(Moore et al. 1980; Stauber et al. 1994; Sun
et al. 2002). This may contribute to the
increased prevalence of upper-extremity
involvement, because lower extremities are
usually protected from cutaneous exposure.
The upper-extremity involvement is unusual
because toxic neuropathies classically begin in
the largest and longest axons in the feet.
Earlier literature of lead neuropathy reported
different patterns of weakness in the upper
extremities based on occupation, which some
believed was due to a myopathy (Aub et al.
1925; Cantarow and Trumper 1944;
Hamilton 1925). The conclusion reached was
that motor activity increased the effects of
lead toxicity (Jacobs and Le Quesne 1984). In
the present study, exposure to ES, used as a
surrogate for active motor units, did interact
with lead exposure but was signiﬁcant only at
IBL60. This is not unexpected because the
earlier literature usually reported motor
involvement presenting as weakness or paraly-
sis only at PbB levels > 60 µg/dL.
Another possible explanation for the
interaction of lead and active motor units is
that nerves affected by lead are more suscepti-
ble to traction or mechanical compression, as
would occur in the carpal tunnel of workers
with exposure to ESs such as heavy lifting and
shoveling. This interaction between a periph-
eral neuropathy and a focal entrapment neu-
ropathy exists in patients with diabetes
(Gilliatt and Willison 1962), Guillain-Barré
syndrome (Lambert and Mulder 1964), and
familial neuropathy (Earl et al. 1964). This
paradigm examined in animal models
revealed that the onset of compression neu-
ropathy in healthy animals took several
months versus a few weeks in animals with an
underlying neuropathy; this latter compres-
sion lesion was more severe (Hopkins and
Morgan-Hughes 1969). Serial electrodiagnos-
tic studies on the upper extremities of lead-
exposed workers showed that the median
nerve was more susceptible to the effects of
lead than was the ulnar nerve (Chia et al.
1996b). This finding may again reflect the
interaction with ES. The principle of
increased susceptibility of a compromised
peripheral nerve to a second insult is well
known in oncology, where patients with
preexisting neuropathy may develop incapaci-
tating toxic neuropathies after the administra-
tion of safe doses of chemotherapeutic agents
(Chaudhry et al. 2003).
The ability to infer a causal relationship
between lead exposure and peripheral nerve
function is limited in a cross-sectional study.
IBL and TWA were based on blood lead lev-
els obtained over the working lifetime of the
participants, thus increasing the likelihood of
any causal inferences made.
In this population of lead smelter work-
ers, nerve function as measured by CPT is
associated with impairment in large and small
myelinated sensory nerve ﬁbers with a thresh-
old effect at a TWA of 28 µg/dL. Peripheral
nerve impairment is associated with markers
of chronic lead exposure, TWA and IBL, but
not PbBn, and may be present when recent
PbB is at an acceptable concentration. Even
with chronic lead exposure, intensity is more
important than duration of exposure. At
higher levels of lead exposure, nerve fibers
affected by lead are more susceptible to the
presence of more active motor units as
reﬂected by ESs.
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Table 3. Unique variance (%) of CPT in the finger
explained by IBL metrics with increasing criterion
blood lead levels.
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